Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Non Operating Income (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Non Operating Income for 4 consecutive years, with $31550.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income rose 89.8% to $31550.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $109044.0, a 104.16% increase, with the full-year FY2024 number at $101464.0, up 222.08% from a year prior.
  • Non Operating Income was $31550.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $13066.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $34106.0 in Q4 2024 to a low of -$13947.0 in Q4 2023.
  • A 4-year average of $18403.0 and a median of $19684.0 in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: skyrocketed 344.54% in 2024, then plummeted 33.62% in 2025.
  • 60 Degrees Pharmaceuticals' Non Operating Income stood at $3172.0 in 2022, then crashed by 539.69% to -$13947.0 in 2023, then surged by 344.54% to $34106.0 in 2024, then decreased by 7.49% to $31550.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Non Operating Income are $31550.0 (Q3 2025), $13066.0 (Q2 2025), and $30322.0 (Q1 2025).